Lapatinib 250 mg film-coated tablets, 30 tablets — generic (India) (Tykerb/Tyverb-equivalent) Treatment of adult breast cancer patients with HER2 (ErbB2) overexpression: Targeted cancer therapy. Drug delivery from Europe and beyond, +380996042415 Viber, WhatsApp

Tykerb / Tyverb / lapatinib

Indications

Treatment of adult patients with HER2 (ErbB2)-positive breast cancer:

As part of combination therapy with capecitabine for patients with advanced or metastatic breast cancer that has progressed on previous therapy with trastuzumab in combination with an anthracycline and taxane for metastatic disease;

As part of combination therapy with trastuzumab for patients with metastatic, hormone-negative breast cancer that has progressed after trastuzumab-containing chemotherapy;

As part of combination therapy with an aromatase inhibitor for postmenopausal women with metastatic, hormone-positive breast cancer who have not received chemotherapy. Patients in the registration study had not been previously treated with trastuzumab or aromatase inhibitors. There are no data on the efficacy of this combination compared to trastuzumab in combination with an aromatase inhibitor in this patient population.

Dosage and Administration

The treatment course should only be prescribed by a physician experienced in the use of anticancer drugs.

Before starting treatment, left ventricular ejection fraction should be determined to ensure that its initial level is within established norms (see the section "Special Instructions for Use"). Left ventricular ejection fraction should be monitored during treatment with Tyverb to ensure that it does not decrease below acceptable limits (see "Discontinuation or Dose Reduction" and "Cardiovascular Adverse Reactions").

Tyverb should be taken 1:00 before or 1:00 after meals (see "Pharmacokinetics"). The recommended daily dose of Tyverb should not be divided. To reduce individual patient variability, Tyverb administration should be standardized around mealtimes, for example, always taking the medication one hour before meals.

Missed doses should not be taken again; the next dose should be continued as scheduled (see Overdose section).

When co-administering with other medications, consult the instructions for use of these medications.

Tyverb in combination with capecitabine.

The recommended dose of Tyverb is 1250 mg (5 tablets) once daily.

The recommended dose of capecitabine is 2000 mg/m2/day given in 2 divided doses (every 12:00) each day from days 1 to 14 of a 21-day treatment cycle. It is recommended to take capecitabine with food or within 30 minutes after a meal.

Tyverb in combination with trastuzumab

The recommended dose of Tyverb is 1000 mg (4 tablets) once daily.

The recommended dose of trastuzumab is 4 mg/kg body weight as a loading dose, then 2 mg/kg body weight once weekly.

Tyverb in combination with an aromatase inhibitor.

The recommended dose of Tyverb is 1500 mg (6 tablets) once daily.

The recommended dose of the aromatase inhibitor letrozole is 2.5 mg once daily. When using Tyverb with an alternative aromatase inhibitor, you should consult the package insert for that drug.